Pages with the most revisions

Jump to navigation Jump to search

Showing below up to 500 results in range #51 to #550.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. Quality factor‏‎ (5 revisions)
  2. High linear energy transfer radiation‏‎ (4 revisions)
  3. S coefficient (radiation weighted)‏‎ (4 revisions)
  4. Non-maleficence‏‎ (4 revisions)
  5. Bioassay‏‎ (4 revisions)
  6. Calculating Radon Doses‏‎ (4 revisions)
  7. Computed tomography dose index‏‎ (4 revisions)
  8. Direct bioassay‏‎ (4 revisions - redirect page)
  9. Alpha decay‏‎ (4 revisions)
  10. Mass median diameter‏‎ (4 revisions)
  11. Math‏‎ (4 revisions)
  12. Effective charge number‏‎ (4 revisions)
  13. Programmed cell death‏‎ (4 revisions)
  14. Averted dose‏‎ (4 revisions)
  15. Effective half-life‏‎ (4 revisions)
  16. Reference Animal and Plant‏‎ (4 revisions)
  17. Kp index‏‎ (4 revisions)
  18. Protective action‏‎ (4 revisions)
  19. Forbiddenness‏‎ (4 revisions)
  20. Aerodynamic diameter‏‎ (4 revisions)
  21. ICRP‏‎ (4 revisions)
  22. Source-related assessment‏‎ (4 revisions)
  23. Reference bioassay function‏‎ (4 revisions)
  24. Risk‏‎ (4 revisions)
  25. Senescence‏‎ (4 revisions)
  26. Diagnostic reference level‏‎ (4 revisions)
  27. Air-kerma, product‏‎ (4 revisions)
  28. Fractionation sensitivity‏‎ (4 revisions)
  29. Optimisation‏‎ (4 revisions)
  30. Air kerma at the patient entrance reference point‏‎ (4 revisions)
  31. Sievert‏‎ (4 revisions)
  32. Absolute risk‏‎ (3 revisions)
  33. Auger transition‏‎ (3 revisions)
  34. Bystander effect‏‎ (3 revisions)
  35. Iso-effect plots‏‎ (3 revisions)
  36. Lifetime risk estimates‏‎ (3 revisions)
  37. Virtue ethics‏‎ (3 revisions)
  38. Emergency procedures‏‎ (3 revisions)
  39. Activity median thermodynamic diameter‏‎ (3 revisions)
  40. Isomers‏‎ (3 revisions)
  41. Complex tissues‏‎ (3 revisions)
  42. Derived air concentration‏‎ (3 revisions)
  43. Voxel phantom‏‎ (3 revisions)
  44. Dignity‏‎ (3 revisions)
  45. Employer‏‎ (3 revisions)
  46. Radiological Protection in Healthcare‏‎ (3 revisions - redirect page)
  47. Growth fraction‏‎ (3 revisions)
  48. Organ dose equivalent‏‎ (3 revisions)
  49. Extrathoracic airways‏‎ (3 revisions)
  50. Galactic cosmic radiation‏‎ (3 revisions)
  51. Growth hormone (somatotropin)‏‎ (3 revisions)
  52. ICRP Publication 103‏‎ (3 revisions)
  53. Excretion rate (instantaneous)‏‎ (3 revisions)
  54. Fairness‏‎ (3 revisions)
  55. Absorption‏‎ (3 revisions)
  56. Recovery‏‎ (3 revisions)
  57. Gamma ray‏‎ (3 revisions)
  58. Spread-out Bragg peak‏‎ (3 revisions)
  59. DNA damage signalling‏‎ (3 revisions)
  60. Field-size effect (Volume effect)‏‎ (3 revisions)
  61. Gastrointestinal syndrome‏‎ (3 revisions)
  62. Biomedical research volunteer‏‎ (3 revisions)
  63. Cardiomyopathy‏‎ (3 revisions)
  64. Wisdom‏‎ (3 revisions)
  65. Dose equivalent‏‎ (3 revisions)
  66. Flexible tissues‏‎ (3 revisions)
  67. Guide to the System of Radiological Protection‏‎ (3 revisions)
  68. Autonomy‏‎ (3 revisions)
  69. Target region‏‎ (3 revisions)
  70. Dose limit‏‎ (3 revisions)
  71. Fluence‏‎ (3 revisions)
  72. Constancy test‏‎ (3 revisions)
  73. Dose‏‎ (3 revisions)
  74. Dose limits‏‎ (3 revisions)
  75. Fluoroscopically guided interventions‏‎ (3 revisions)
  76. Annual dose‏‎ (3 revisions)
  77. DS02‏‎ (3 revisions)
  78. Potential exposure‏‎ (3 revisions)
  79. Accountability‏‎ (3 revisions)
  80. Half-life, physical‏‎ (3 revisions)
  81. Rigidity threshold‏‎ (3 revisions)
  82. Cell death‏‎ (3 revisions)
  83. Low Earth orbit‏‎ (3 revisions)
  84. Contamination‏‎ (3 revisions)
  85. X ray‏‎ (3 revisions)
  86. Dose of record (E)‏‎ (3 revisions)
  87. Exponential survival curve‏‎ (3 revisions)
  88. Annual limit on intake‏‎ (3 revisions)
  89. Unsealed source‏‎ (3 revisions)
  90. Xerostomia‏‎ (3 revisions)
  91. Graded approach‏‎ (3 revisions)
  92. Interphase death‏‎ (3 revisions)
  93. Test‏‎ (3 revisions)
  94. Dose per content function‏‎ (3 revisions)
  95. Public exposure‏‎ (3 revisions)
  96. Equity‏‎ (3 revisions)
  97. Fractionation‏‎ (3 revisions)
  98. Uptake‏‎ (3 revisions)
  99. Active (red) bone marrow‏‎ (3 revisions)
  100. Granulocyte-macrophage colony-stimulating factor‏‎ (3 revisions)
  101. Utilitarian ethics‏‎ (3 revisions)
  102. Operational quantity‏‎ (3 revisions)
  103. Granulocyte colony-stimulating factor‏‎ (3 revisions)
  104. Coster-Kronig transition‏‎ (3 revisions)
  105. Value judgement‏‎ (3 revisions)
  106. Gray‏‎ (3 revisions)
  107. Valvular heart disease‏‎ (3 revisions)
  108. Personal dose equivalent‏‎ (3 revisions)
  109. Principle of justification‏‎ (3 revisions)
  110. Emergency preparedness‏‎ (3 revisions)
  111. Radiofrequency ablation‏‎ (3 revisions)
  112. Representative organism (non-human biota)‏‎ (2 revisions)
  113. ICRPædia Guide to the Basics of Ionising Radiation‏‎ (2 revisions)
  114. Beta-minus decay‏‎ (2 revisions)
  115. Clearance level‏‎ (2 revisions)
  116. Threshold dose for tissue reactions‏‎ (2 revisions)
  117. Magnetosphere‏‎ (2 revisions)
  118. Dose constraint‏‎ (2 revisions)
  119. Early normal tissue responses‏‎ (2 revisions)
  120. Radiographer‏‎ (2 revisions)
  121. Exposure situation‏‎ (2 revisions)
  122. Growth factor‏‎ (2 revisions)
  123. Alimentary tract transfer factor‏‎ (2 revisions)
  124. Representative person‏‎ (2 revisions)
  125. Safety‏‎ (2 revisions)
  126. Beta-plus decay‏‎ (2 revisions)
  127. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  128. Specific effective energy‏‎ (2 revisions)
  129. Limitation of dose‏‎ (2 revisions)
  130. Cumulative dose‏‎ (2 revisions)
  131. Transmission detection system‏‎ (2 revisions)
  132. Multistage tumorigenesis‏‎ (2 revisions)
  133. Non-sphericity parameter‏‎ (2 revisions)
  134. Dose conversion coefficient‏‎ (2 revisions)
  135. Pharynx‏‎ (2 revisions)
  136. Edema‏‎ (2 revisions)
  137. Excess relative risk‏‎ (2 revisions)
  138. Exposure to Radon at Home‏‎ (2 revisions)
  139. GATA binding protein 2‏‎ (2 revisions)
  140. Reproductive integrity‏‎ (2 revisions)
  141. Hormones‏‎ (2 revisions)
  142. Authorization‏‎ (2 revisions)
  143. Safety case‏‎ (2 revisions)
  144. Slow repair‏‎ (2 revisions)
  145. Isotropic geometry‏‎ (2 revisions)
  146. Clonogenic cells‏‎ (2 revisions)
  147. Lineal energy‏‎ (2 revisions)
  148. Thyroid blocking‏‎ (2 revisions)
  149. Curie‏‎ (2 revisions)
  150. Transparency‏‎ (2 revisions)
  151. Waste disposal‏‎ (2 revisions)
  152. Non-targeted effects‏‎ (2 revisions)
  153. Effect Dose 50‏‎ (2 revisions)
  154. Procedural values‏‎ (2 revisions)
  155. Endogeneous excretion‏‎ (2 revisions)
  156. Reasonableness‏‎ (2 revisions)
  157. Acute radiation syndrome‏‎ (2 revisions)
  158. Residual dose‏‎ (2 revisions)
  159. Hounsfield unit‏‎ (2 revisions)
  160. Authorized limit‏‎ (2 revisions)
  161. Safety culture‏‎ (2 revisions)
  162. Solar cosmic radiation‏‎ (2 revisions)
  163. Inhalability‏‎ (2 revisions)
  164. Cardiac arrhythmias‏‎ (2 revisions)
  165. Spontaneous fission‏‎ (2 revisions)
  166. Itinerant (radiation) worker‏‎ (2 revisions)
  167. Clonogenic survival‏‎ (2 revisions)
  168. Linear-non-threshold model‏‎ (2 revisions)
  169. Cytokines‏‎ (2 revisions)
  170. Trapped particles‏‎ (2 revisions)
  171. Orphan source‏‎ (2 revisions)
  172. Planned exposure situation‏‎ (2 revisions)
  173. Progenitor cell‏‎ (2 revisions)
  174. Radiation belt‏‎ (2 revisions - redirect page)
  175. Adaptive response‏‎ (2 revisions)
  176. Alveolar-interstitial region‏‎ (2 revisions)
  177. Respiratory protection‏‎ (2 revisions)
  178. Autoimmune disease‏‎ (2 revisions)
  179. Scintigraphy‏‎ (2 revisions)
  180. Solar cycle‏‎ (2 revisions)
  181. Inner bremsstrahlung‏‎ (2 revisions)
  182. ICRP Publication 118‏‎ (2 revisions)
  183. Cardiac valve diseases‏‎ (2 revisions)
  184. Systemic model‏‎ (2 revisions)
  185. Linear-quadratic dose response model‏‎ (2 revisions)
  186. Time factor‏‎ (2 revisions)
  187. Myocardial perfusion‏‎ (2 revisions)
  188. What is Radon?‏‎ (2 revisions)
  189. Disposal‏‎ (2 revisions)
  190. Dose criteria‏‎ (2 revisions)
  191. Platelet-derived growth factor‏‎ (2 revisions)
  192. Environmental exposure‏‎ (2 revisions)
  193. Radiation modifier‏‎ (2 revisions)
  194. Exempt waste‏‎ (2 revisions)
  195. Radiological protection principles‏‎ (2 revisions)
  196. Recovery (cellular or tissue)‏‎ (2 revisions)
  197. Retrievability‏‎ (2 revisions)
  198. Immune system‏‎ (2 revisions)
  199. Institutional control‏‎ (2 revisions)
  200. Stakeholder‏‎ (2 revisions)
  201. Co-expertise‏‎ (2 revisions)
  202. Tachycardia‏‎ (2 revisions)
  203. Connective tissue‏‎ (2 revisions)
  204. Tissue equivalent material‏‎ (2 revisions)
  205. DRL process‏‎ (2 revisions)
  206. Myocardial stress test‏‎ (2 revisions)
  207. Oversight‏‎ (2 revisions)
  208. Projected dose‏‎ (2 revisions)
  209. Environmental radiation protection‏‎ (2 revisions)
  210. Exemption level‏‎ (2 revisions)
  211. Radionuclides of natural origin‏‎ (2 revisions)
  212. Radioresponsiveness‏‎ (2 revisions)
  213. Recovery responder‏‎ (2 revisions)
  214. Gastroschisis‏‎ (2 revisions)
  215. Angiogenesis‏‎ (2 revisions)
  216. Reversibility‏‎ (2 revisions)
  217. Hyperbaric oxygen‏‎ (2 revisions)
  218. In vivo radiobioassay‏‎ (2 revisions)
  219. Bioturbation‏‎ (2 revisions)
  220. Solar particle event‏‎ (2 revisions)
  221. Cardioverter-defibrillator‏‎ (2 revisions)
  222. Consequential late effects‏‎ (2 revisions)
  223. Worker‏‎ (2 revisions)
  224. Nuclear track detectors‏‎ (2 revisions)
  225. Effective dose equivalent‏‎ (2 revisions)
  226. Radiation safety officer‏‎ (2 revisions)
  227. Existing exposure situation‏‎ (2 revisions)
  228. Radiosensitiser‏‎ (2 revisions)
  229. Acceptance test‏‎ (2 revisions)
  230. Gastrulation‏‎ (2 revisions)
  231. Rehabilitation of living conditions‏‎ (2 revisions)
  232. Habitual mouth breather‏‎ (2 revisions)
  233. Annihilation photons‏‎ (2 revisions)
  234. Right to know‏‎ (2 revisions)
  235. Hyperfractionation‏‎ (2 revisions)
  236. Incidence‏‎ (2 revisions)
  237. Bone marrow‏‎ (2 revisions)
  238. Solar wind‏‎ (2 revisions)
  239. Cohort study‏‎ (2 revisions)
  240. Target tissue‏‎ (2 revisions)
  241. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  242. DRL value‏‎ (2 revisions)
  243. Working level‏‎ (2 revisions)
  244. OLINDA/EXM‏‎ (2 revisions)
  245. Particle radiance‏‎ (2 revisions)
  246. Protection strategy‏‎ (2 revisions)
  247. Epithelium‏‎ (2 revisions)
  248. Radiation source‏‎ (2 revisions)
  249. Radiosensitivity, cellular‏‎ (2 revisions)
  250. Adventitious‏‎ (2 revisions)
  251. Habitual nose breather‏‎ (2 revisions)
  252. Rigidity‏‎ (2 revisions)
  253. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  254. Background dose (rate)‏‎ (2 revisions)
  255. Security‏‎ (2 revisions)
  256. Incident‏‎ (2 revisions)
  257. Intermediate level waste‏‎ (2 revisions)
  258. Stenosis‏‎ (2 revisions)
  259. Local DRL‏‎ (2 revisions)
  260. Containment‏‎ (2 revisions)
  261. Tolerability‏‎ (2 revisions)
  262. Medical exposure‏‎ (2 revisions)
  263. Naturally occurring radioactive material‏‎ (2 revisions)
  264. Working level month‏‎ (2 revisions)
  265. Dose-length product‏‎ (2 revisions)
  266. Equieffective dose‏‎ (2 revisions)
  267. Expanded and aligned radiation field‏‎ (2 revisions)
  268. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  269. Hypoplasia‏‎ (2 revisions)
  270. Backscatter detection system‏‎ (2 revisions)
  271. Inclusiveness‏‎ (2 revisions)
  272. Bradycardia‏‎ (2 revisions)
  273. Source-related‏‎ (2 revisions)
  274. Internal conversion electron‏‎ (2 revisions)
  275. LD 50/30‏‎ (2 revisions)
  276. Telangiectasia‏‎ (2 revisions)
  277. Member of the public‏‎ (2 revisions)
  278. Unattached fraction‏‎ (2 revisions)
  279. Necrosis‏‎ (2 revisions)
  280. Detriment‏‎ (2 revisions)
  281. Dose-rate effect‏‎ (2 revisions)
  282. Patient entrance reference point‏‎ (2 revisions)
  283. Potential recoverability correction factor‏‎ (2 revisions)
  284. Electron-capture decay‏‎ (2 revisions)
  285. Protective action guide‏‎ (2 revisions)
  286. Radiation worker‏‎ (2 revisions)
  287. Radon: Units of Measure‏‎ (2 revisions)
  288. Accreditation‏‎ (2 revisions)
  289. Reference air kerma‏‎ (2 revisions)
  290. Genomic integrity‏‎ (2 revisions)
  291. Hazard‏‎ (2 revisions)
  292. Self-help protection‏‎ (2 revisions)
  293. Individual-related‏‎ (2 revisions)
  294. Bragg peak‏‎ (2 revisions)
  295. Storage‏‎ (2 revisions)
  296. Coronary heart disease‏‎ (2 revisions)
  297. Track structure‏‎ (2 revisions)
  298. Mendelian diseases‏‎ (2 revisions)
  299. Decay constant‏‎ (2 revisions)
  300. Neurological syndrome‏‎ (2 revisions)
  301. Occupational exposure‏‎ (2 revisions)
  302. Peak skin dose‏‎ (2 revisions)
  303. Dose of record Hp (10)‏‎ (2 revisions)
  304. Electrophysiology‏‎ (2 revisions)
  305. Radioactive dispersion device‏‎ (2 revisions)
  306. Fractional absorption in the gastrointestinal tract‏‎ (2 revisions)
  307. Action Level‏‎ (2 revisions)
  308. Health Surveillance‏‎ (2 revisions)
  309. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  310. Basal cell‏‎ (2 revisions)
  311. Individual decontamination‏‎ (2 revisions)
  312. Branching fraction‏‎ (2 revisions)
  313. Chronic exposure‏‎ (2 revisions)
  314. Subcutaneous tissue‏‎ (2 revisions)
  315. Colony‏‎ (2 revisions)
  316. Low dose rate‏‎ (2 revisions)
  317. Cosmic Radiation in Aviation‏‎ (2 revisions)
  318. Transfer compartment‏‎ (2 revisions)
  319. Mitigation‏‎ (2 revisions)
  320. Decommissioning‏‎ (2 revisions)
  321. Upper reference levels‏‎ (2 revisions)
  322. Neurovascular syndrome‏‎ (2 revisions)
  323. Dose-threshold‏‎ (2 revisions)
  324. Pelagic‏‎ (2 revisions)
  325. Practical radiological protection culture‏‎ (2 revisions)
  326. Radioactive source‏‎ (2 revisions)
  327. Exposure, external or internal‏‎ (2 revisions)
  328. Reference biokinetic model‏‎ (2 revisions)
  329. Graft vs host disease‏‎ (2 revisions)
  330. Air-kerma, incident‏‎ (2 revisions)
  331. Relocation‏‎ (2 revisions)
  332. Heliosphere‏‎ (2 revisions)
  333. Risk coefficient‏‎ (2 revisions)
  334. Individual monitoring‏‎ (2 revisions)
  335. Source term‏‎ (2 revisions)
  336. Class SR-0 gases‏‎ (2 revisions)
  337. Latent time/period or latency interval‏‎ (2 revisions)
  338. Low level waste‏‎ (2 revisions)
  339. Decontamination‏‎ (2 revisions)
  340. Diastasis‏‎ (2 revisions)
  341. Dose per unit intake coefficient‏‎ (2 revisions)
  342. Emergency‏‎ (2 revisions)
  343. Qualified expert‏‎ (2 revisions)
  344. Radioactive substance‏‎ (2 revisions)
  345. Exposure (in the context of inhalation)‏‎ (2 revisions)
  346. Radon Recommendations for Authorities‏‎ (2 revisions)
  347. Fractionation and dose delivery patterns‏‎ (2 revisions)
  348. Reference individual‏‎ (2 revisions)
  349. Remedial action‏‎ (2 revisions)
  350. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  351. Broad beam therapy irradiation technique‏‎ (2 revisions)
  352. Intervention Level‏‎ (2 revisions)
  353. Class SR-1 gases‏‎ (2 revisions)
  354. Substantial radiation dose level‏‎ (2 revisions)
  355. Committed effective dose‏‎ (2 revisions)
  356. Cost-benefit analysis‏‎ (2 revisions)
  357. Transfer rate‏‎ (2 revisions)
  358. Multi-detector computed tomography‏‎ (2 revisions)
  359. Decontamination factor‏‎ (2 revisions)
  360. Percutaneous coronary intervention‏‎ (2 revisions)
  361. Dose rate‏‎ (2 revisions)
  362. Prevailing circumstances‏‎ (2 revisions)
  363. Emergency exposure situation‏‎ (2 revisions)
  364. Erythropoietin‏‎ (2 revisions)
  365. ALARA‏‎ (2 revisions)
  366. Radon Recommendations for Workplaces‏‎ (2 revisions)
  367. Reference level‏‎ (2 revisions)
  368. Remediation‏‎ (2 revisions)
  369. Hierarchical tissues‏‎ (2 revisions)
  370. Area monitoring‏‎ (2 revisions)
  371. Risk of Exposure to Radon‏‎ (2 revisions)
  372. Benthic‏‎ (2 revisions)
  373. Bronchial region‏‎ (2 revisions)
  374. South Atlantic anomaly‏‎ (2 revisions)
  375. Interventional procedure‏‎ (2 revisions)
  376. Class SR-2 gases‏‎ (2 revisions)
  377. Committed equivalent dose‏‎ (2 revisions)
  378. Lymphatic system‏‎ (2 revisions)
  379. Transforming growth factor‏‎ (2 revisions)
  380. Dichotomous‏‎ (2 revisions)
  381. Pericarditis‏‎ (2 revisions)
  382. Dose rate effectiveness factor‏‎ (2 revisions)
  383. Principle of application of dose limits‏‎ (2 revisions)
  384. Emergency plan‏‎ (2 revisions)
  385. Ethics‏‎ (2 revisions)
  386. Radioactivity‏‎ (2 revisions)
  387. Activity‏‎ (2 revisions)
  388. Repopulation‏‎ (2 revisions)
  389. High level waste‏‎ (2 revisions)
  390. Routine monitoring‏‎ (2 revisions)
  391. ICRPædia Guide to Radon‏‎ (2 revisions)
  392. Special (non-routine) monitoring‏‎ (2 revisions)
  393. Clearance‏‎ (2 revisions)
  394. Lifetime risk‏‎ (2 revisions)
  395. Macrophage colony stimulating factor‏‎ (2 revisions)
  396. Multiplicative risk projection model‏‎ (2 revisions)
  397. Deontological Ethics‏‎ (2 revisions)
  398. Differentiation‏‎ (2 revisions)
  399. Exposure pathway‏‎ (1 revision)
  400. Ras‏‎ (1 revision)
  401. Functional subunits‏‎ (1 revision)
  402. Activity median aerodynamic diameter‏‎ (1 revision)
  403. Reference phantom‏‎ (1 revision)
  404. Ground-level enhancement‏‎ (1 revision)
  405. ICRP Publication 90‏‎ (1 revision)
  406. ICRP Publication 101a‏‎ (1 revision)
  407. Size-specific dose estimate‏‎ (1 revision)
  408. ICRP Publication 114‏‎ (1 revision)
  409. Specific absorbed fraction‏‎ (1 revision)
  410. ICRP Publication 129‏‎ (1 revision)
  411. Surface contamination‏‎ (1 revision)
  412. ICRP Publication 143‏‎ (1 revision)
  413. Compartment (environmental)‏‎ (1 revision)
  414. ICRP Publication 18‏‎ (1 revision)
  415. Cross section‏‎ (1 revision)
  416. Translocation‏‎ (1 revision)
  417. Multistage carcinogenesis model‏‎ (1 revision)
  418. ICRP Publication 30 (Part 1)‏‎ (1 revision)
  419. Deposition‏‎ (1 revision)
  420. ICRP Publication 39‏‎ (1 revision)
  421. Digital breast tomosynthesis‏‎ (1 revision)
  422. ICRP Publication 53‏‎ (1 revision)
  423. Phantom‏‎ (1 revision)
  424. ICRP Publication 68‏‎ (1 revision)
  425. ICRP Publication 82‏‎ (1 revision)
  426. Excess absolute risk‏‎ (1 revision)
  427. Rb‏‎ (1 revision)
  428. Reference value‏‎ (1 revision)
  429. ICRP Publication 91‏‎ (1 revision)
  430. Homologous recombination‏‎ (1 revision)
  431. Authorised discharge‏‎ (1 revision)
  432. ICRP Publication 101b‏‎ (1 revision)
  433. Slice‏‎ (1 revision)
  434. ICRP Publication 115‏‎ (1 revision)
  435. ICRP Publication 13‏‎ (1 revision)
  436. Clinical audit‏‎ (1 revision)
  437. ICRP Publication 144‏‎ (1 revision)
  438. Threshold level‏‎ (1 revision)
  439. ICRP Publication 19‏‎ (1 revision)
  440. ICRP Publication 30 (Part 2)‏‎ (1 revision)
  441. ICRP Publication 4‏‎ (1 revision)
  442. Organ at risk‏‎ (1 revision)
  443. ICRP Publication 54‏‎ (1 revision)
  444. ICRP Publication 69‏‎ (1 revision)
  445. Principles of protection‏‎ (1 revision)
  446. ICRP Publication 83‏‎ (1 revision)
  447. Radiation-induced second cancer‏‎ (1 revision)
  448. Reactive oxygen species‏‎ (1 revision)
  449. Acute exposure‏‎ (1 revision)
  450. Reference worker‏‎ (1 revision)
  451. Allometry‏‎ (1 revision)
  452. ICRP Publication 92‏‎ (1 revision)
  453. ICRP Publication 102‏‎ (1 revision)
  454. Informed consent‏‎ (1 revision)
  455. ICRP Publication 116‏‎ (1 revision)
  456. Spongiosa‏‎ (1 revision)
  457. ICRP Publication 130‏‎ (1 revision)
  458. ICRP Publication 145‏‎ (1 revision)
  459. Marrow cellularity‏‎ (1 revision)
  460. ICRP Publication 2‏‎ (1 revision)
  461. Multitarget equation‏‎ (1 revision)
  462. ICRP Publication 30 (Part 3)‏‎ (1 revision)
  463. Derived consideration reference level‏‎ (1 revision)
  464. ICRP Publication 40‏‎ (1 revision)
  465. ICRP Publication 55‏‎ (1 revision)
  466. Dose conversion convention‏‎ (1 revision)
  467. Pilomatricoma‏‎ (1 revision)
  468. ICRP Publication 7‏‎ (1 revision)
  469. ICRP Publication 84‏‎ (1 revision)
  470. Radiation-induced secondary malignancy‏‎ (1 revision)
  471. Exclusion‏‎ (1 revision)
  472. Radiological attack‏‎ (1 revision)
  473. Referrer‏‎ (1 revision)
  474. ICRP Publication 93‏‎ (1 revision)
  475. ICRU 4-element tissue‏‎ (1 revision)
  476. Biological half-life‏‎ (1 revision)
  477. ICRP Publication 117‏‎ (1 revision)
  478. ICRP Publication 131‏‎ (1 revision)
  479. System of radiological protection‏‎ (1 revision)
  480. ICRP Publication 146‏‎ (1 revision)
  481. Concentration ratio‏‎ (1 revision)
  482. Time-resolved computed tomography‏‎ (1 revision)
  483. ICRP Publication 20‏‎ (1 revision)
  484. Mutation component‏‎ (1 revision)
  485. ICRP Publication 30 (Part 4)‏‎ (1 revision)
  486. Derived investigation level‏‎ (1 revision)
  487. Waste management‏‎ (1 revision)
  488. Normal tissue complication probability‏‎ (1 revision)
  489. ICRP Publication 41‏‎ (1 revision)
  490. Directional dose equivalent‏‎ (1 revision)
  491. ICRP Publication 56‏‎ (1 revision)
  492. Dose conversion factor‏‎ (1 revision)
  493. ICRP Publication 70‏‎ (1 revision)
  494. Effect modifier‏‎ (1 revision)
  495. ICRP Publication 85‏‎ (1 revision)
  496. Endosteum‏‎ (1 revision)
  497. Radiological controlled area‏‎ (1 revision)
  498. Region‏‎ (1 revision)
  499. ICRP Publication 94‏‎ (1 revision)
  500. Human Alimentary Tract Model‏‎ (1 revision)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:MostRevisions"